Michael Grissinger has served as a member of our board of directors since November 2018. Mr. Grissinger has decades of experience in business development and licensing leadership roles at global pharmaceutical companies. He recently retired from Johnson & Johnson, Inc. in April 2018 after a 25-year career beginning in January 1996. During his tenure at Johnson & Johnson, Mr. Grissinger held various positions including Vice President Mergers and Acquisitions Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018, Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016, Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the board of Akari Therapeutics, Plc (AKTX). Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.